The Melanocortin System: α-MSH, NPY, Galanin, and Melanocortin-Receptor Pharmacology

The melanocortin family comprises five G-protein-coupled receptors (MC1R, MC2R, MC3R, MC4R, MC5R), all Gs-coupled and elevating intracellular cAMP when activated. Each has a distinct tissue distribution and endogenous ligand preference: MC1R is expressed on melanocytes and signals pigmentation; MC2R is the adrenocortical ACTH receptor driving cortisol and aldosterone synthesis; MC3R and MC4R are CNS receptors with central roles in energy balance and appetite; MC5R is expressed in exocrine glands (sebaceous, lacrimal, and others).

The endogenous ligands of this system all originate from proopiomelanocortin (POMC), a 267-amino-acid prohormone processed in a tissue-specific pattern by prohormone convertases (PC1 and PC2) and carboxypeptidase E. In the anterior pituitary, POMC is cleaved primarily into ACTH and β-lipotropin, serving the HPA axis. In the intermediate pituitary (in species that have one) and in hypothalamic POMC neurons, PC2-dominant processing cleaves ACTH further into α-MSH (the acetylated N-terminal 13-residue peptide) and corticotropin-like intermediate-lobe peptide (CLIP). β-lipotropin is processed to γ-lipotropin and β-endorphin; γ-lipotropin yields β-MSH in humans. γ-MSH derives from the N-terminal region of POMC itself.

Receptor-ligand selectivity follows a loose hierarchy: α-MSH binds MC1R, MC3R, MC4R, and MC5R with relatively balanced affinity; ACTH is the main MC2R agonist and also binds the others at high concentrations; β-MSH preferentially binds MC4R; γ-MSH binds MC3R with some selectivity. Agouti-signaling protein (ASIP) and agouti-related peptide (AgRP) are endogenous inverse agonists — ASIP antagonizes MC1R in skin, AgRP antagonizes MC3R/MC4R in hypothalamus.

α-MSH (alpha-melanocyte-stimulating hormone) is a 13-amino-acid peptide with an N-terminal acetyl group and a C-terminal amide — Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 — and it is the best-characterized melanocortin in human physiology. Named for its original identification as a pigmentary hormone, α-MSH actions extend well beyond melanin synthesis.

In skin, α-MSH binds MC1R on melanocytes, activating cAMP-PKA signaling, upregulating tyrosinase and MITF expression, and shifting melanogenesis from red-yellow pheomelanin toward brown-black eumelanin. Individual MC1R variants that produce loss-of-function signaling (common in red-haired, fair-skinned populations) explain inherited differences in sun response and melanoma risk. Topical α-MSH and analogs have been studied for pigmentary disorders but face the problem that MC1R activation also requires UV or inflammatory co-stimulation for robust pigmentation.

In hypothalamus, α-MSH released by POMC neurons in the arcuate nucleus binds MC4R on second-order neurons in the paraventricular nucleus, producing a satiety signal that reduces food intake and increases energy expenditure. Loss-of-function mutations in MC4R are the most common monogenic cause of human obesity, accounting for 2–5% of early-onset severe obesity. MC3R has a related but distinct role in nutrient partitioning.

In the immune system, α-MSH and related melanocortin peptides suppress proinflammatory cytokine production, attenuate neutrophil recruitment, and promote regulatory macrophage phenotypes. This anti-inflammatory action occurs through MC1R and MC3R on immune cells, and it is the mechanistic rationale for ACTH-analog therapy (repository corticotropin, Acthar gel) in multiple sclerosis and nephrotic syndrome.

Proopiomelanocortin is encoded by the POMC gene on chromosome 2p23. The 267-residue preprohormone is synthesized in POMC neurons of the hypothalamic arcuate nucleus, in the anterior and intermediate pituitary, in placenta, and in several immune cell populations. Its processing pattern depends on the complement of prohormone convertases (PC1, PC2) and carboxypeptidase E expressed in each tissue.

In the anterior pituitary, PC1 predominates, producing ACTH, N-terminal POMC fragments (including γ-MSH precursor segments), and β-lipotropin. β-lipotropin is further processed to γ-lipotropin and β-endorphin. In hypothalamic POMC neurons and the intermediate pituitary, PC2 cleaves ACTH further to α-MSH and CLIP, and β-LPH to β-MSH plus β-endorphin.

Genetic defects along the POMC-processing pathway cause distinct human obesity syndromes. POMC deficiency (mutations in POMC itself) produces early-onset severe obesity, adrenal insufficiency, and red hair. PCSK1 deficiency (mutations in PC1) produces a similar phenotype due to failed ACTH, α-MSH, and insulin processing. LEPR deficiency (leptin receptor mutations) prevents the leptin-driven activation of POMC neurons. These three syndromes share the final common pathway of reduced MC4R activation, and all three respond to setmelanotide, the FDA-approved MC4R agonist, which bypasses the genetic block by directly stimulating the downstream receptor.

The POMC-melanocortin axis is additionally modulated by leptin (stimulates POMC neurons), insulin, ghrelin (inhibits POMC neurons and activates NPY/AgRP neurons), and glucose signals. This integration makes POMC a convergence point for peripheral metabolic signals and central energy balance.

Setmelanotide (Imcivree, Rhythm Pharmaceuticals) is a cyclic octapeptide MC4R-selective agonist, approved by the FDA in 2020 for chronic weight management in adults and children aged six and older with obesity due to POMC, PCSK1, or LEPR deficiency confirmed by genetic testing. The indication was expanded in 2022 to include Bardet-Biedl syndrome, and further expansions for hypothalamic obesity and other rare syndromes have been pursued.

In the pivotal trials, patients with these genetic obesity syndromes lost 20–26% of baseline body weight over 52 weeks — effect sizes larger than semaglutide or tirzepatide in general obesity. The drug is administered as a daily subcutaneous injection. Common adverse events include injection-site reactions, skin hyperpigmentation (due to incidental MC1R activation), and nausea. Setmelanotide does not approved for common (polygenic) obesity; pivotal trials in that population did not meet weight-loss thresholds sufficient for approval, likely because the MC4R pathway is less rate-limiting when POMC processing is intact.

Setmelanotide is the cleanest clinical demonstration of the melanocortin system's central role in human energy balance. It also illustrates the practical limits of the pathway — the drug works best when a specific upstream defect creates MC4R understimulation that can be bypassed by direct agonism. In common obesity, multiple pathways contribute and single-target MC4R agonism is less transformative.

Melanotan II, discussed in its own profile, is an older research-chemical hexapeptide MC1R/MC3R/MC4R agonist that was developed in the 1980s at the University of Arizona for tanning. Unlike setmelanotide, melanotan II lacks MC4R selectivity, produces substantial pigmentation through MC1R activation, and has no FDA approval. The two compounds share the broader melanocortin-agonist class but occupy different regulatory and pharmacological spaces.

Energy balance in the hypothalamus is governed by a push-pull architecture. POMC/α-MSH neurons in the arcuate nucleus produce anorexigenic (satiety-promoting) signals via MC4R. A separate population of arcuate neurons co-expressing neuropeptide Y (NPY) and agouti-related peptide (AgRP) produces orexigenic (feeding-promoting) signals via Y-receptor activation and simultaneous AgRP antagonism of MC4R. These two populations are reciprocally innervated and respond oppositely to leptin, ghrelin, and metabolic cues.

NPY is a 36-amino-acid peptide, one of the most abundant neuropeptides in mammalian brain, and one of the most potent appetite stimulants known — ventricular NPY injection in satiated rats produces immediate voracious feeding. Its actions are mediated through Y1, Y2, Y4, Y5, and Y6 receptors; Y1R and Y5R on hypothalamic neurons mediate the feeding response. NPY additionally reduces energy expenditure, lowers sympathetic tone, and promotes fat storage, producing a coordinated pro-storage metabolic state.

In physiological appetite regulation, NPY/AgRP neurons fire in response to fasting, low leptin, and high ghrelin; POMC neurons fire in response to feeding, high leptin, and insulin. Loss of POMC input or constitutive NPY/AgRP activity produces hyperphagia and obesity, and this axis is the target of both GLP-1 receptor agonists (which act upstream to suppress appetite through multiple mechanisms) and setmelanotide (which bypasses NPY/AgRP antagonism of MC4R).

Pharmacologically, NPY Y5 receptor antagonists were developed as obesity drugs in the 2000s, but clinical trials produced modest weight loss and some cardiovascular-safety concerns. The class has largely been displaced by GLP-1 receptor agonists, which produce far larger weight loss by engaging multiple pathways including melanocortin signaling indirectly.

Galanin is a 29- or 30-amino-acid neuropeptide expressed widely in CNS and peripheral tissues, with three receptor subtypes (GALR1, GALR2, GALR3) that couple to Gi/o and G11/Gq signaling depending on subtype. Galanin has roles in feeding behavior, pain modulation, nociception, cognition, mood regulation, and seizure threshold.

In the context of feeding, paraventricular and arcuate nucleus galanin signaling is orexigenic, with a preferential effect on fat consumption. Galanin neurons in the paraventricular nucleus respond to high-fat dietary exposure, creating a positive feedback loop that promotes continued fat intake. Galanin also modulates reward and addiction circuits — galanin receptor agonists attenuate opioid withdrawal and ethanol self-administration in some animal models.

Alongside NPY, galanin is one of several orexigenic peptides counterbalancing melanocortin satiety signals. Its physiological role in total energy balance is more modest than NPY's, and galanin-targeted drugs have not advanced meaningfully into obesity or metabolic therapeutics. Research interest has been stronger in pain (GALR1/GALR2-selective agonists as non-opioid analgesics), epilepsy (galanin is anticonvulsant in several seizure models), and mood disorders.

Together, α-MSH, NPY, and galanin illustrate the layered, multi-peptide architecture of hypothalamic feeding regulation. Monotherapy targeting any single node produces partial effects, which is why multi-pathway drugs (GLP-1/GIP dual agonists, GLP-1/GIP/glucagon triple agonists) have proven more transformative than single-receptor interventions in common obesity.